旭化成医疗器械（杭州）有限公司

What 旭化成医疗器械（杭州）有限公司 does

旭化成医疗器械（杭州）有限公司 (Asahi Kasei Medical (Hangzhou) Co., Ltd.) is a wholly-owned Chinese manufacturing subsidiary of Asahi Kasei Medical Co., Ltd. of Japan, established on November 21, 2003 in the Hangzhou Economic and Technological Development Zone with USD 20 million in registered capital. The company manufactures and sells hollow-fiber dialyzers under the APS™ and REXEED™ product families, and blood-purification consumables including Plasmaflo OP, Cascadeflo EC, IMMUSORBA PH/TR, PLASORBA BR, EXCELFLO, CUREFLO, and CELLSORBA for therapeutic apheresis and artificial liver support indications. Underlying technology is based on proprietary polysulfone hollow-fiber membrane engineering and adsorption technology inherited from the Japanese parent, with annual production capacity of 8.74 million dialyzers after a 2014 expansion that added approximately 940,000 units.

The company sells medical-device consumables primarily to hospitals and dialysis centers across China, supported by branch offices in Beijing, Shanghai, and Guangzhou. Go-to-market is event-driven, anchored on participation in clinical congresses such as the National Liver Failure Conference, the Blood Purification Forum (BPF 2019), the East China Nephrology Forum, and the Critical Care Medicine Congress, indicating reliance on academic key opinion leaders and clinical-evidence marketing rather than direct-to-consumer channels. As a subsidiary within Asahi Kasei Medical's global network, which reaches more than 70 countries, the Hangzhou entity also functions as a manufacturing and export node for the parent's international distribution system. The legal representative is Maruyama Hiroyuki (丸山裕之).

The business model is hardware/consumable unit sales of regulated medical devices, with revenue tied to chronic hemodialysis treatment volumes and, to a lesser extent, therapeutic-apheresis procedure volumes in hepatology and critical care. The company does not disclose revenue, pricing, or utilization metrics. End-customer concentration is diffuse across hospital accounts but is structurally dependent on a single therapeutic area (renal replacement therapy) and on NMPA reimbursement policy for dialysis consumables in China.

Name

旭化成医疗器械（杭州）有限公司

Legal name

旭化成医疗器械（杭州）有限公司

Website

https://amc.net.cn

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Asahi Kasei Medical (Hangzhou) Co., Ltd. is a wholly-owned Chinese subsidiary of Japan's Asahi Kasei Medical that manufactures polysulfone hollow-fiber dialyzers (APS™, REXEED™) and blood-purification consumables for hospitals and dialysis centers in China, with 8.74 million units of annual capacity.

Ownership category

akta.pro rank

Product category

Medical Devices - Dialysis and Blood Purification

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Dialyzers (Artificial Kidneys) (HLAHAKAC)

akta.pro secondary industries

Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges) (HLAHAKAH), Dialysis Water Treatment & Dialysate Delivery Systems (HLAHAKAD)

Keywords

• Hemodialysis products
• Blood purification devices
• Artificial kidney dialyzers
• Medical device manufacturing
• Plasma exchange therapy

Headquarters

HQ city

杭州

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Dialysis products (人工肾脏/透析器): Production and sales of hollow fiber dialyzers, the company's primary revenue stream, with production capacity of 8.74 million units per year.
2. Blood purification products (血液净化产品): Sales of blood purification therapy related products including CRRT products, plasma exchange consumables, and therapeutic devices.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

旭化成医疗器械（杭州）有限公司 manufactures and sells hollow fiber dialyzers (artificial kidneys) and blood purification therapy products for hemodialysis, plasma exchange, CRRT, and leukocyte removal therapy. Its core products are polysulfone membrane artificial kidneys (APS™ and REXEED™ series) and a portfolio of blood purification consumables (Plasmaflo OP, Cascadeflo EC, IMMUSORBA PH/TR, PLASORBA BR, EXCELFLO, CUREFLO, CELLSORBA). The company operates an annual production capacity of 8.74 million hollow fiber dialyzers, serving hospitals and healthcare institutions in China and over 70 countries worldwide.

Product overview

旭化成医疗器械（杭州）有限公司 is a wholly-owned subsidiary of Asahi Kasei Medical (Japan), specializing in medical devices for blood purification therapy. The company operates two main business segments: (1) Dialysis Products including REXEED™ series, APS™ series dialyzers using polysulfone membrane technology, and Dialysis System MDS-101; and (2) Blood Purification Therapy Products including plasma exchange consumables (Plasmaflo OP, Cascadeflo EC), selective plasma adsorbers (IMMUSORBA PH/TR, PLASORBA BR), CRRT products (EXCELFLO, CUREFLO), and LCAP therapy products (CELLSORBA). The company serves patients in over 70 countries, focusing on membrane separation technology to develop hollow fiber artificial kidneys and blood purification systems.

Differentiator

Problem solved

Functional benefit

Brands

• REXEED™: High-performance polysulfone membrane artificial kidney with excellent biocompatibility and permeability
• APS™
• PlasautoΣ
• REXEED™ Series
• Plasmaflo OP
• Cascadeflo EC
• IMMUSORBA PH/TR
• PLASORBA BR
• EXCELFLO
• CUREFLO
• CELLSORBA

Products and services

• REXEED™

Quantifiable outcome

• Products supplied to over 70 countries worldwide
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• 中华医学会/中华医学会感染病学分会肝衰竭与人工肝学组coreStrategic or Co-development Partner · 21 March 2019Co-participation in the 10th National Liver Failure and Artificial Liver Academic Conference, where Asahi Kasei Medical served as an exhibitor and hosted satellite symposiums with Japanese medical professors presenting on blood purification therapies for liver failure.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Shandong Weigao Group Medical Polymer: Major Chinese medical device manufacturer with diverse portfolio including dialysis consumables, syringes, and orthopedic products. Broad incumbent in Chinese medical device market with growing dialysis product line.

Direct peers

• Baxter International: Major player in dialysis and blood purification through its Vantive kidney care business, offering dialyzers, CRRT products (including PRISMAFLEX), and plasma exchange therapies. Direct competitor in CRRT and blood purification consumables.
• B. Braun: German medical device and pharmaceutical company with significant dialysis and blood purification product portfolio (Diacap, xevonta dialyzers). Direct competitor in dialyzer and CRRT markets globally.
• Fresenius Medical Care: Global dialysis market leader with comprehensive dialyzer, dialysis machine, and dialysis services portfolio. Directly competes in the same hollow fiber dialyzer and blood purification consumables category worldwide.
• NxStage Medical (Fresenius): Now part of Fresenius Medical Care, pioneered home dialysis and CRRT systems. Direct competitor in CRRT and portable dialysis equipment that complements the company's filter consumables.
• Toray Medical Co., Ltd. Subsidiary of Toray Industries that produces polysulfone hollow fiber dialyzers and artificial kidneys. Direct Japanese competitor in the same polysulfone membrane dialyzer category with strong technology overlap.
• Asahi Kasei Medical Co., Ltd. Parent company and global market leader in dialysis and blood purification with the same polysulfone membrane technology (APS, REXEED). The Hangzhou subsidiary is effectively its Chinese manufacturing arm, making it the most directly comparable peer.
• Nipro Corporation: Japanese-headquartered medical device company with significant hollow fiber dialyzer manufacturing (Nipro brand). Competes directly in polysulfone membrane dialyzers and global dialysis markets, particularly in Asia.

Emerging players

• Outset Medical: US-based innovator in home dialysis technology with the Tablo system. Emerging player in dialysis equipment with overlapping customer base in nephrology, though focused on hardware rather than consumables.
• Jafron Biomedical Co., Ltd. Leading Chinese blood purification company headquartered in Zhuhai, specializing in hemoperfusion cartridges and blood purification products. Emerging competitor in Chinese blood purification market with rapidly growing scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E6%97%AD%E5%8C%96%E6%88%90%E5%8C%BB%E7%96%97%E5%99%A8%E6%A2%B0%EF%BC%88%E6%9D%AD%E5%B7%9E%EF%BC%89%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 旭化成医疗器械（杭州）有限公司